Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Partnered Content
Ask the Analyst
RSS Feeds
Subscribe
Advertise
Contact Us
FAQs
Reports Store
UsernamePublicRestriction
Tags:
Biosimilars Deals India

Cipla And Alvotech Prime Emerging Markets Push With Adalimumab Deal

  • Analysis

Executive Summary

Cipla has firmed up a commercialization deal with Alvotech for the Icelandic developer’s high-concentration version of AbbVie’s Humira, continuing to use the licensing approach to expand its biosimilar franchise in emerging markets.

You may also be interested in...



Alvotech Gears Up For Public Listing With Fresh Leadership

Alvotech has brought in public markets specialist Tanya Zharov as deputy CEO for the firm in Iceland, as it prepares for a public listing.

Alvotech And Prestige Strike Biosimilar Manufacturing Deal

Alvotech and Prestige Biopharma have announced a new contract manufacturing partnership for one of Prestige’s biosimilar candidates.

Cipla Sees Muted First Quarter Amid Distributor 'Churn' In India

A significant shake-up of distributors in the Indian market impacted Cipla’s first-quarter earnings but the firm expects to bounce back. Biosimilars in emerging markets and opportunities in China are among the growth drivers it is banking on.

Table

View full table

Related Content

Generics Bulletin
Generics Bulletin
Generics Bulletin
Scrip
Generics Bulletin
Scrip

Topics

Related Companies

Tags:
Biosimilars Deals India
UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By